4
MARKET OVERVIEW
Outlines emerging trends, technology impact, and regulatory signals affecting growth trajectory and stakeholder decisions.
4.3
INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.4
STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5
INDUSTRY TRENDS
Highlights the market structure, growth drivers, restraints, and near-term inflection points influencing performance.
5.1
PORTER'S FIVE FORCES ANALYSIS
5.2
MACROECONOMIC INDICATORS
5.2.2
GDP TRENDS & FORECAST
5.2.3
TRENDS IN MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS INDUSTRY
5.5.1
AVERAGE SELLING PRICE TREND OF KEY PLAYERS (2024–2026)
5.5.2
AVERAGE SELLING PRICE TREND OF MOLECULAR DIAGNOSTICS INSTRUMENTS, BY TYPE (2024–2026)
5.7
KEY CONFERENCES & EVENTS, 2026–2027
5.8
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.9
INVESTMENT & FUNDING SCENARIO
5.10
IMPACT OF 2025 US TARIFFS ON MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS MARKET
5.10.3
PRICE IMPACT ANALYSIS
5.10.4
IMPACT ON END-USER INDUSTRIES
6
STRATEGIC DISRUPTIONS THROUGH TECHNOLOGY, PATENTS, AND DIGITAL & AI ADOPTION
6.1
KEY EMERGING TECHNOLOGIES
6.2
COMPLEMENTARY TECHNOLOGIES
6.3
TECHNOLOGY/PRODUCT ROADMAP
6.5
IMPACT OF AI/GEN AI ON MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS MARKET
6.5.1
TOP USE CASES & MARKET POTENTIAL
6.5.2
CASE STUDIES OF AI IMPLEMENTATION IN MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS MARKET
6.5.3
INTERCONNECTED ADJACENT ECOSYSTEMS & IMPACT ON MARKET PLAYERS
6.5.4
CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS MARKET
7.1
REGIONAL REGULATIONS & COMPLIANCE
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1
DECISION-MAKING PROCESS
8.2
BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
8.3
ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4
UNMET NEEDS FROM VARIOUS END-USER INDUSTRIES
9
MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (MARKET SIZE & FORECAST TO 2031 – USD MILLION)
10
MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE (MARKET SIZE & FORECAST TO 2031 – USD MILLION)
11
MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE (MARKET SIZE & FORECAST TO 2031 – USD MILLION)
11.2
BLOOD, SERUM, AND PLASMA
12
MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (MARKET SIZE & FORECAST TO 2031 – USD MILLION)
12.2
POLYMERASE CHAIN REACTION
12.3
ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY
12.4
DNA SEQUENCING & NEXT-GENERATION SEQUENCING
12.5
IN SITU HYBRIDIZATION
13
MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (MARKET SIZE & FORECAST TO 2031 – USD MILLION)
13.2
INFECTIOUS DISEASE DIAGNOSTICS
13.2.1
SEXUALLY TRANSMITTED DISEASES
13.2.1.5
OTHER SEXUALLY TRANSMITTED DISEASES
13.2.2.3
OTHER HEPATITIS DISEASES
13.2.3
RESPIRATORY INFECTIOUS DISEASES
13.2.3.4
OTHER RESPIRATORY INFECTIOUS DISEASES
13.2.4
HOSPITAL-ACQUIRED INFECTIONS
13.2.5
VECTOR-BORNE DISEASES
13.2.6
OTHER INFECTIOUS DISEASES
13.3.5
OTHER CANCER TYPES
14
MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE (MARKET SIZE & FORECAST TO 2031 – USD MILLION)
15
MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS MARKET, BY CLINICAL APPLICATION (MARKET SIZE & FORECAST TO 2031 – USD MILLION)
16
MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS MARKET, BY END USER (MARKET SIZE & FORECAST TO 2031 – USD MILLION)
16.3
DIAGNOSTIC LABORATORIES
17
MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY (MARKET SIZE & FORECAST TO 2031 – USD MILLION)
17.2.7
REST OF MIDDLE EAST
18.2
KEY PLAYER STRATEGIES/RIGHT TO WIN
18.3
REVENUE ANALYSIS, 2021–2025
18.4
MARKET SHARE ANALYSIS,
18.5
COMPANY VALUATION & FINANCIAL METRICS
18.7
COMPANY EVALUATION MATRIX: KEY PLAYERS,
18.7.5
COMPANY FOOTPRINT: KEY PLAYERS,
18.7.5.1
COMPANY FOOTPRINT
18.7.5.2
PRODUCT & SERVICE FOOTPRINT
18.7.5.3
TEST TYPE FOOTPRINT
18.7.5.4
SAMPLE TYPE FOOTPRINT
18.7.5.5
APPLICATION FOOTPRINT
18.8
COMPANY EVALUATION MATRIX: STARTUPS/SMES,
18.8.1
PROGRESSIVE COMPANIES
18.8.2
RESPONSIVE COMPANIES
18.8.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES,
18.8.5.1
DETAILED LIST OF KEY STARTUPS/SMES
18.8.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
18.9
COMPETITIVE SCENARIO
19.1.1
DANAHER CORPORATION
19.1.2
F. HOFFMANN-LA ROCHE LTD.
19.1.4
SIEMENS HEALTHINEERS AG
19.1.5
THERMO FISHER SCIENTIFIC INC.
19.1.11
BECTON, DICKINSON AND COMPANY
19.1.12
MYRIAD GENETICS, INC.
19.1.13
QUIDELORTHO CORPORATION
19.1.16
EXACT SCIENCES CORPORATION
19.1.17
GENETIC SIGNATURES
19.2.1
AGILENT TECHNOLOGIES, INC.
19.2.4
BRUKER CORPORATION
19.2.5
AMOY DIAGNOSTICS CO., LTD.
19.2.7
SAVYON DIAGNOSTICS
20.1.1.1
KEY DATA FROM SECONDARY SOURCES
20.1.3
MARKET SIZE ESTIMATION
20.1.3.1
BOTTOM-UP APPROACH
20.1.3.2
TOP-DOWN APPROACH
20.1.3.3
BASE NUMBER CALCULATION
20.1.4
MARKET FORECAST APPROACH
20.1.5
DATA TRIANGULATION
20.1.7
RESEARCH ASSUMPTIONS
20.1.8
RESEARCH LIMITATIONS & RISK ASSESSMENT
21.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
21.3
CUSTOMIZATION OPTIONS
Growth opportunities and latent adjacency in Middle East & Africa Molecular Diagnostics Market